Nov 29, 2022 / 05:35PM GMT
Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division - Analyst
All right. Welcome, everyone. This is Gavin Clark-Gartner from the Evercore ISI Biotech research team, and I'm very happy to be here with the team from Incyte. We have Herve Hoppenot, the Chairman and CEO; Christiana Stamoulis, CFO; and Jim Lee, who is the Head of Information and Autoimmunity Development. Thanks so much for joining us.
Herve Hoppenot - Incyte Corporation - Chairman, President & CEO
Thank you for having us.
Questions and Answers:
Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division - AnalystYes, absolutely. So we have 20 minutes for our fireside. So we're going to jump right into some more specific question and answers. And maybe the point to start is actually with the Inflation Reduction Act. And first, I just wanted to confirm you have met the small biotech exemption criteria, correct, for -- [at least for Jakafi]. So negotiated price couldn't go